See Oxidien’s 90 second presentation of the opportunity that came in Top 3 in the Life Science Nation’s Innovation Challenge

2° Hyperoxaluria

Secondary hyperoxaluria is a disease with significant unmet medical need. Patients demonstrate wide ranging severity, from manageable symptoms to severe and chronic complications.

There are two types of Secondary (2°) Hyperoxaluria : Idiopathic Hyperoxaluria (IH) and Enteric Hyperoxaluria (EH) 1, 2, 3 .

IH is the most common type, and mostly observed in individuals with calcium oxalate kidney stones 1, 4, 5 .
EH is partly caused by an underlying gastrointestinal complication associated with a malabsorption of oxalate. In these patients, oxalate becomes more available for absorption 2 , which can cause severe kidney damage and can lead to end-stage renal failure.

View References

Products

OX-1

OX-1 is a novel oxalate decarboxylase (OxDC) enzyme developed with the support of multiple National Institute of Health (NIH) Small Business Innovation Research (SBIR) Grants. OX-1 demonstrates stability in a wide pH range including very acidic environments; thus, can effectively degrade oxalate in the gastrointestinal tract, in particular the stomach.

A Prospective, Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study Utilizing Orally Administered Oxalate Decarboxylase (OxDC) To Reduce Urinary Oxalate.

(Pending Peer-Review)

In Vitro And In Vivo Safety Evaluation of Ox-1

Download Study Summary

AA-1

AA-1(also known as A0) is an oxalate decarboxylase (OxDC) enzyme originating from a fungal source. AA-1 has the potential to degrade oxalate throughout the complete gastrointestinal tract due to its extremely wide pH activity profile with activity in neutral and basic pH range.

Urinary Oxalate by Enzymatic Reduction of Dietary and Endogenous Oxalate, an abstract and poster featuring research partner, Captozyme, and their A0 research.

Download Abstract